Combination therapy for ulcerative colitis: Orally targeted nanoparticles prevent mucosal damage and relieve inflammation

Theranostics

Volumn 6, Issue 12, 2016, Pages 2250-2266

  Xiao, Bo ^a,b   Zhang, Zhan ^b   Viennois, Emilie ^b,c   Kang, Yuejun ^a   Zhang, Mingzhen ^b   Han, Moon Kwon ^b   Chen, Jiucun ^a   Merlin, Didier ^b,c  

^a SOUTHWEST UNIVERSITY   (China)

^b GEORGIA STATE UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Anti inflammation; Combination therapy; Mucosal protection; Oral administration; Targeted nanoparticle; Ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; CURCUMIN; NANOPARTICLE; SMALL INTERFERING RNA CD98; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; CD98 ANTIGEN; DRUG CARRIER; HYALURONIC ACID; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; COLON EPITHELIAL CELL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; INTESTINE EPITHELIUM CELL; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; ULCERATIVE COLITIS; ZETA POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; COLITIS, ULCERATIVE; COLON; COMBINATION DRUG THERAPY; DRUG EFFECTS; EPITHELIUM CELL; INFLAMMATION; INTESTINE MUCOSA; METABOLISM; MOLECULARLY TARGETED THERAPY; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD98; BIOLOGICAL PRODUCTS; CELL LINE; COLITIS, ULCERATIVE; COLON; CURCUMIN; DRUG CARRIERS; DRUG THERAPY, COMBINATION; EPITHELIAL CELLS; HYALURONIC ACID; INFLAMMATION; INTESTINAL MUCOSA; LACTIC ACID; MACROPHAGES; MALE; MICE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; POLYGLYCOLIC ACID; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 84995470108     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.15710     Document Type: Article

References (60)

1. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology. 2007;133:1099-105.
2. Hang TTN, Dalmasso G, Torkvist L, Halfvarson J, Yan YT, Laroui H, et al. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. J Clin Invest. 2011;121:1733-47.
3. Abraham C, Cho JH. Mechanisms of disease: Inflammatory Bowel Disease. New Engl J Med. 2009;361:2066-78.
4. Xiao B, Laroui H, Ayyadurai S, Viennois E, Charania MA, Zhang YC, et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials. 2013;34:7471-82.
5. Laroui H, Theiss AL, Yan Y, Dalmasso G, Nguyen HT, Sitaraman SV, et al. Functional TNFalpha gene silencing mediated by polyethyleneimine/TNFalpha siRNA nanocomplexes in inflamed colon. Biomaterials. 2011;32:1218-28.
6. Yan YT, Vasudevan S, Nguyen HTT, Merlin D. Intestinal epithelial CD98: An oligomeric and multifunctional protein. Biochim Biophys Acta. 2008;1780:1087-92.
7. Hang TTN, Merlin D. Homeostatic and innate immune responses: role of the transmembrane glycoprotein CD98. Cell Mol Life Sci. 2012;69:3015-26.
8. Kucharzik T, Lugering A, Yan Y, Driss A, Charrier L, Sitaraman S, et al. Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation. Lab Invest. 2005;85:932-41.
9. Cantor JM, Ginsberg MH. CD98 at the crossroads of adaptive immunity and cancer. J Cell Sci. 2012;125:1373-82.
10. Xiao B, Laroui H, Viennois E, Ayyadurai S, Charania MA, Zhang Y, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146:1289-300.
11. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63:629-42.
12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
13. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125-35.
14. Park JS, Yang HN, Jeon SY, Woo DG, Kim MS, Park KH. The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis. Biomaterials. 2012;33:8600-12.
15. Sun TM, Du JZ, Yao YD, Mao CQ, Dou S, Huang SY, et al. Simultaneous Delivery of siRNA and Paclitaxel via a "Two-in-One" Micelleplex Promotes Synergistic Tumor Suppression. ACS nano. 2011;5:1483-94.
16. Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT. Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment. ACS nano. 2013;7:9571-84.
17. Xu XY, Xie K, Zhang XQ, Pridgen EM, Park GY, Cui DS, et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A. 2013;110:18638-43.
18. Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion. 2012;85:249-55.
19. Pu HL, Chiang WL, Maiti B, Liao ZX, Ho YC, Shim MS, et al. Nanoparticles with Dual Responses to Oxidative Stress and Reduced pH for Drug Release and Anti-inflammatory Applications. ACS nano. 2014;8:1213-21.
20. Gupta SC, Patchva S, Aggarwal BB. Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. AAPS J. 2013;15:195-218.
21. Xiong XB, Lavasanifar A. Traceable Multifunctional Micellar Nanocarriers for Cancer-Targeted Co-delivery of MDR-1 siRNA and Doxorubicin. ACS nano. 2011;5:5202-13.
22. Biswas S, Deshpande PP, Navarro G, Dodwadkar NS, Torchilin VR. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials. 2013;34:1289-301.
23. Dong DW, Xiang B, Gao W, Yang ZZ, Li JQ, Qi XR. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Biomaterials. 2013;34:4849-59.
24. Zhao J, Mi Y, Feng SS. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials. 2013;34:3411-21.
25. Xiao B, Han MK, Viennois E, Wang L, Zhang M, Si X, et al. Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale. 2015;7:17745-55.
26. Xiao B, Yang Y, Viennois E, Zhang YC, Ayyadurai S, Baker MT, et al. Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticles. J Mater Chem B Mater Biol Med. 2014;2:1499-508.
27. Xiao B, Merlin D. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin Drug Deliv. 2012;9:1393-407.
28. Lamprecht A. IBD Selective nanoparticle adhesion can enhance colitis therapy. Nat Rev Gastro Hepat 2010;7:311-2.
29. Fromont Hankard G, Cezard JP, Aigrain Y, Navarro J, Peuchmaur M. CD44 variant expression in inflammatory colonic mucosa is not disease specific but associated with increased crypt cell proliferation. Histopathology. 1998;32:317-21.
30. Farkas S, Hornung M, Sattler C, Anthuber M, Gunthert U, Herfarth H, et al. Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol. 2005;142:260-7.
31. Dreaden EC, Morton SW, Shopsowitz KE, Choi JH, Deng ZJ, Cho NJ, et al. Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-by-Layer (LbL) Nanoparticles. ACS nano. 2014;8:8374-82.
32. Lavertu M, Methot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials. 2006;27:4815-24.
33. Badawy MEI, Rabea EI. Potential of the biopolymer chitosan with different molecular weights to control postharvest gray mold of tomato fruit. Postharvest Biol Technol. 2009;51:110-7.
34. Xiao B, Si X, Han MK, Viennois E, Zhang M, Merlin D. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B Mater Biol Med. 2015;3:7724-33.
35. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D, et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur J Pharm Biopharm. 2011;77:26-35.
36. Cun D, Foged C, Yang M, Frokjaer S, Nielsen HM. Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm. 2010;390:70-5.
37. Laroui H, Geem D, Xiao B, Viennois E, Rakhya P, Denning T, et al. Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol Ther. 2014;22:69-80.
38. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release. 2009;133:90-5.
39. Mora-Huertas CE, Fessi H, Elaissari A. Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification-diffusion methods Critical comparison. Adv Colloid Interface Sci. 2011;163:90-122.
40. Chen YF, Rosenzweig Z. Luminescent CdSe quantum dot doped stabilized micelles. Nano Lett. 2002;2:1299-302.
41. Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: Effects of the emulsifier and drug loading ratio. Pharm Res. 2003;20:1864-72.
42. Hassan CM, Peppas NA. Structure and applications of poly(vinyl alcohol) hydrogels produced by conventional crosslinking or by freezing/thawing methods. Adv Polym Sci. 2000;153:37-65.
43. Mora-Huertas CE, Fessi H, Elaissari A. Influence of process and formulation parameters on the formation of submicron particles by solvent displacement and emulsification-diffusion methods critical comparison. Adv Colloid Interface Sci. 2011;163:90-122.
44. Xiao B, Zhang M, Viennois E, Zhang Y, Wei N, Baker MT, et al. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials. 2015;48:147-60.
45. MacDermott RP. Chemokines in the inflammatory bowel diseases. J Clin Immunol. 1999;19:266-72.
46. Lewis K, Caldwell J, Phan V, Prescott D, Nazli A, Wang A, et al. Decreased epithelial barrier function evoked by exposure to metabolic stress and nonpathogenic E. coli is enhanced by TNF-alpha. Am J Physiol Gastrointest Liver Physiol. 2008;294:G669-78.
47. Theiss AL, Laroui H, Obertone TS, Chowdhury I, Thompson WE, Merlin D, et al. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm Bowel Dis. 2011;17:1163-76.
48. Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012;2012:718617.
49. Grisham MB. Do different animal models of IBD serve different purposes? Inflamm Bowel Dis. 2008;14:S132-3.
50. Patel MV, Patel KB, Gupta SN. Effects of Ayurvedic treatment on forty-three patients of ulcerative colitis. Ayu. 2010;31:478-81.
51. Yang T, Li B, Qi S, Liu Y, Gai Y, Ye P, et al. Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. Theranostics. 2014;4:1096-111.
52. Yu H, Guo C, Feng B, Liu J, Chen X, Wang D, et al. Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer. Theranostics. 2016;6:14-27.
53. Park JS, Yang HN, Jeon SY, Woo DG, Kim MS, Park KH. The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis. Biomaterials. 2012;33:8600-12.
54. Desai PR, Marepally S, Patel AR, Voshavar C, Chaudhuri A, Singh M. Topical delivery of anti-TNFalpha siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release. 2013;170:51-63.
55. Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138:843-53.
56. Laroui H, Viennois E, Xiao B, Canup BS, Geem D, Denning TL, et al. Fab'-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release. 2014;186:41-53.
57. Kim TH, Ihm JE, Choi YJ, Nah JW, Cho CS. Efficient gene delivery by urocanic acid-modified chitosan. J Control Release. 2003;93:389-402.
58. Liu Y, Reineke TM. Hydroxyl stereochemistry and amine number within poly(glycoamidoamine)s affect intracellular DNA delivery. J Am Chem Soc. 2005;127:3004-15.
59. Zhang S, Ermann J, Succi MD, Zhou A, Hamilton MJ, Cao B, et al. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease. Sci Transl Med. 2015;7:300ra128.
60. Farkas S, Hornung M, Sattler C, Anthuber M, Gunthert U, Herfarth H, et al. Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol. 2005;142:260-7.